Gedeon Richter (RICHTER) Q4 2025 earnings summary

Executive summary

• 2025 ended with strong revenue and Clean EBIT growth exceeding guidance at constant exchange rates, despite geopolitical risks, currency headwinds, and regulatory uncertainty.

• Pharma revenues rose 8.3% YoY (CER) to EUR 2.31bn, Clean EBIT up 14% YoY (CER), and Q4 performance was particularly robust, boosting full-year profitability.

• Sentiment around hormonal therapies improved, benefiting the Women's Health segment, and the company advanced environmental initiatives, achieving a 14% reduction in CO2 emissions from 2021 levels.

• Free cash flow increased 2% YoY, supporting record-high dividends and minor acquisitions, while net profit declined 3% YoY due to FX losses and higher effective tax rate.

• Vraylar exclusivity was extended by six months, now lasting four more years, and the year concluded with strong Q4 results, outperforming profitability guidance and meeting adjusted revenue targets.

Financial highlights

• FY2025 pharma revenues: HUF 914bn (+8.2% YoY); Q4 revenues up 12.5% YoY; Clean EBIT (pharma) up 14% YoY to HUF 305bn; Q4 Clean EBIT up 37% YoY.

• Gross margin reached 69.5%, up from previous years, and gross profit grew 8% YoY to HUF 635bn.

• Free cash flow reached HUF 250bn (+2% YoY), supporting record-high dividends and minor acquisitions.

• Net profit was HUF 232.3bn (-3% YoY), with FX losses of HUF 25.3bn and higher taxes weighing on EPS.

• Return on equity at 16.6%.

Outlook and guidance

• 2026 guidance targets high single-digit growth in both revenues and Clean EBIT, with continued focus on raising non-CNS profit margins and efficiency projects.

• R&D-to-sales ratio is projected to rise to 11% in 2026, driven by clinical projects in CNS and Women's Health.

• Clean EBIT will be unevenly distributed across quarters in 2026 due to seasonality and R&D volatility.

• EUR 100mn restructuring expenses expected 2026–2030, mainly for IT upgrades.

• Launch of Feel Revie (E4) in menopause indication is planned for H2 2026, with initial revenues expected to be small but ramping up in larger markets.